BioPharma Dive November 9, 2023
Delilah Alvarado

The pharma paid $400 million to license the drug from Hutchmed earlier this year in an effort to bolster its oncology business.

Dive Brief:

  • The Food and Drug Administration on Wednesday approved a new targeted therapy for metastatic colon cancer, granting an OK to Furzaqla from Takeda.
  • The drug is cleared for adults with previously treated metastatic colorectal cancer, regardless of what protein markers their tumors express. Takeda claims it’s the first drug that targets all three subtypes of an important cellular regulator known as VEGF.
  • Known scientifically as fruquintinib, Fruzaqla won its clearance several weeks ahead of the FDA’s target Nov. 30 decision date. It’s already approved for colon cancer in China, where it’s marketed as Elunate by...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
The Holy Grail of Biology
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations

Share This Article